Rules-Based Medicine Pulls IPO | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rules-Based Medicine is pulling its initial public offering citing adverse market conditions.

In a document filed with the US Securities and Exchange Commission on Tuesday, the Austin, Texas-based multiplex molecular diagnostics firm said it plans to withdraw its IPO due to market conditions, but it did not elaborate further. A company spokesman also declined to comment further on the withdrawal of the IPO.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.